• Home
  •  / BenevolentAI

BenevolentAI

OverviewSuggest Edit

BenevolentAI is a company that combines advanced AI and machine learning with science aiming to decipher complex disease biology, generate novel insights, and discover more effective medicines. Its computational R&D platform spans every step of the drug discovery process, powering an in-house pipeline of drug programmes from early discovery towards clinical phases. BenevolentAI has also discovered a repurposed drug candidate for COVID-19.

TypePrivate
Founded2013
HQLondon, GBMap
Websitebenevolent.com
Employee Ratings4.7More
View Jobs (8)

Recent NewsAll News

Latest Updates

Employees (est.) (Sept 2021)316
Job Openings8
Revenue (FY, 2018)£6.8 M(+165%)
Cybersecurity ratingAMore

Key People/Management at BenevolentAI

Joanna Shields

Joanna Shields

CEO
Ivan Griffin

Ivan Griffin

COO & Co-Founder
Anne Phelan

Anne Phelan

CSO
Rob Quinn

Rob Quinn

CFO
Michael Brennan

Michael Brennan

Co-Founder & Head of Corporate Development
Mark Davies

Mark Davies

SVP Informatics and Data
Show more

BenevolentAI Office Locations

BenevolentAI has offices in London, Babraham and New York
London, GB (HQ)
4-8 Maple St, Bloomsbury
Babraham, GB
Babraham Hall House
New York, NY, US
1 Dock 72 Way, 7th Floor
Show all (3)

BenevolentAI Financials and Metrics

Summary Metrics

Founding Date

2013

BenevolentAI total Funding

$305 m

BenevolentAI latest funding size

$90 m

Time since last funding

2 years ago

BenevolentAI investors

Temasek Holdings, Lundbeck, Woodford Investment Management, Lansdowne Partners, Upsher Smith Laboratories
BenevolentAI's latest funding round in September 2019 was reported to be $90 m. In total, BenevolentAI has raised $305 m. BenevolentAI's latest valuation is reported to be $1 b.
View all funding rounds

BenevolentAI Revenue

Embed Graph
View revenue for all periods
BenevolentAI's revenue was reported to be £6.83 m in FY, 2018 which is a 164.1% increase from the previous period.
GBP

Revenue (FY, 2018)

6.8m

Revenue growth (FY, 2017 - FY, 2018), %

164.1%

Gross profit (FY, 2018)

6.8m

Gross profit margin (FY, 2018), %

100%

Net income (FY, 2018)

(26.9m)

EBIT (FY, 2018)

(32.6m)

Market valuation

1.0b

Cash (31-Dec-2018)

32.5m
GBPFY, 2017FY, 2018

Revenue

2.6m6.8m

Revenue growth, %

164%

Gross profit

2.6m6.8m

Gross profit Margin, %

100%100%
show all
GBPFY, 2017FY, 2018

Cash

19.6m32.5m

Prepaid Expenses

337.0k1.1m

Current Assets

27.0m46.6m

PP&E

393.0k4.5m
show all
GBPFY, 2017FY, 2018

Net Income

(30.4m)(26.9m)

Depreciation and Amortization

3.3m748.0k

Accounts Payable

(592.0k)2.8m

Cash From Operating Activities

(19.3m)(37.9m)
show all
GBPFY, 2017

Revenue/Employee

42.3k

Financial Leverage

0.6 x
Show all financial metrics

BenevolentAI Operating Metrics

May, 2020

Trademarks Pending

2
Show all operating metrics

BenevolentAI Acquisitions / Subsidiaries

Company NameDateDeal Size
BenevolentAI Cambridge LimitedFebruary 21, 2018
BenBio GK
BenevolentAI Bio Limited
BenevolentAI Energy Limited
BenevolentAI Technology Inc
BenevolentAI Technology Limited

BenevolentAI Revenue Breakdown

Embed Graph

BenevolentAI revenue breakdown by business segment: 91.4% from License Revenue and 8.6% from Rendering of Services

BenevolentAI revenue breakdown by geographic segment: 90.3% from Europe, 8.6% from USA and 1.2% from Other

Human Capital Metrics

Source: uploads5.craft.co, uploads4.craft.co
Embed Graph
Show all human capital metrics

BenevolentAI Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

Learn more about our premium products
SecurityScorecard logo

BenevolentAI Online and Social Media Presence

BenevolentAI's Trends

Embed Graph

BenevolentAI News and Updates

July 09, 2021

BenevolentAI announces the appointment of biopharma luminary Dr François Nader as Chairman

LONDON, July 9, 2021 /PRNewswire/ -- BenevolentAI announces the appointment of Dr François Nader as Chairman. Dr Nader is an experienced biopharma executive currently serving as Chairman of Talaris, Acceleron Pharma, independent Board Director at Moderna and Alexion and as a senior...
February 11, 2021

BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial

LONDON, Feb. 11, 2021 /PRNewswire/ -- BenevolentAI, a leader in the application of AI and machine learning in drug discovery and development, announced dosing of the first patient in its randomised first-in-human clinical trial of BEN-2293, a molecule designed and developed by...
January 27, 2021

BenevolentAI and AstraZeneca achieve collaboration milestone with novel AI-generated chronic kidney disease target

LONDON, Jan. 27, 2021 /PRNewswire/ -- BenevolentAI today announced that the biopharmaceutical company AstraZeneca has selected a novel chronic kidney disease (CKD) target to advance to its drug development portfolio, making it the first AI-generated target from the collaboration to enter...
May 05, 2020

How BenevolentAI bounced back from a $1 billion loss

When London tech startup BenevolentAI secured a $90 million (£68 million) cash injection from Singaporean sovereign fund Temasek in September 2019, the deal valued the business at $1 billion. Not bad for a six-year-old company whose ambition to dramatically change the way drugs are discovered and de…
May 04, 2020

COVID-19 update: Possible cure found by BenevolentAI

By using high-end BenevolentAI technologies, a possible treatment was found and pinpointed in such a speedy manner that shocked the company that makes the said drug, and as well as the other doctors who had spent years into researching about the effects on other viruses.
April 18, 2020

In the time of Covid pandemic, AI comes to the rescue

An Artificial Intelligence (AI) software developed by BenevolentAI, a London-based startup has created a super search engine that combines the data from the drug industry data and chunks of new information garnered from scientific research papers.
Show more

BenevolentAI Blogs

April 11, 2020

Potential treatment for COVID-19 identified by BenevolentAI using artificial intelligence enters clinical testing

In response to the global coronavirus pandemic, BenevolentAI announced that baricitinib is entering clinical testing as a potential treatment for COVID-19. BenevolentAI identified the drug in recent research by using artificial intelligence and machine learning. The trial by Eli Lilly will inves…
March 17, 2020

Future Fifty: joining forces to drive forward positive change

BenevolentAI today announced it has been selected for Tech Nation’s 2020 Future Fifty cohort. In this blog, BenevolentAI’s CEO Joanna Shields reflects on how joining forces with like minded industry experts can serve as a powerful vehicle for transformation.
March 11, 2020

International Women’s Day: A Conversation with Four Female Colleagues

For International Women’s Day we hosted a fireside chat in London with four of our inspiring female colleagues to learn more about their experiences, successes and the barriers or challenges they've faced as a woman in a largely male dominated industry.
March 08, 2020

How historically neglecting sex differences have impacted women’s health.

Sex differences have historically been neglected in clinical research, design and practice. To mark International Women’s Day, we explored the implications of this ‘one size fits all’ approach to medical research and treatment for women’s health.
March 08, 2020

How historically neglecting sex differences has impacted women’s health

Sex differences have historically been neglected in clinical research, design and practice. To mark International Women’s Day, we explored the implications of this ‘one size fits all’ approach to medical research and treatment for women’s health.
March 03, 2020

Medical data: the key to unlocking the true potential of AI in healthcare

The biomedical research data-gap risks worsening health inequality, and will be exacerbated in the age of artificial intelligence if action is not taken now. In a recent panel at Benevolent, technology and healthcare experts discussed the data diversity issue and proposed solutions.
Show more

 BenevolentAI Frequently Asked Questions

  • When was BenevolentAI founded?

    BenevolentAI was founded in 2013.

  • Who are BenevolentAI key executives?

    BenevolentAI's key executives are Joanna Shields, Ivan Griffin and Anne Phelan.

  • How many employees does BenevolentAI have?

    BenevolentAI has 316 employees.

  • What is BenevolentAI revenue?

    Latest BenevolentAI annual revenue is £6.8 m.

  • What is BenevolentAI revenue per employee?

    Latest BenevolentAI revenue per employee is £21.6 k.

  • Who are BenevolentAI competitors?

    Competitors of BenevolentAI include LabGenius, SOM Biotech and Paige.

  • Where is BenevolentAI headquarters?

    BenevolentAI headquarters is located at 4-8 Maple St, Bloomsbury, London.

  • Where are BenevolentAI offices?

    BenevolentAI has offices in London, Babraham and New York.

  • How many offices does BenevolentAI have?

    BenevolentAI has 3 offices.